PNT insider filings

POINT Biopharma Global Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-12-27. Screen PNT transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for PNT between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — POINT Biopharma Global Inc.

FiledFormInsiderReported transactionsSource
2023-12-274GOODMAN JONATHAN R. — DirectorCode (U): 41,872 · Disposition to issuer (D): 35,872 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative)EDGAR
2023-12-274KELLY JUSTYNA — Chief Operating OfficerDisposition to issuer (D): 26,904 (derivative) · Disposition to issuer (D): 4,932 (derivative) · Disposition to issuer (D): 70,000 (derivative) · Disposition to issuer (D): 77,958 (derivative) · Disposition to issuer (D): 98,358 (derivative)EDGAR
2023-12-274MCCANN JOE A. — Chief Executive Officer, DirectorCode (U): 2,160 · Code (U): 3,494,153 · Disposition to issuer (D): 381,795 (derivative) · Disposition to issuer (D): 692,643 (derivative)EDGAR
2023-12-274JENSEN JESSICA D. — EVP Clinical DevelopmentDisposition to issuer (D): 125,553 (derivative) · Disposition to issuer (D): 461,250 (derivative) · Disposition to issuer (D): 213,301 (derivative) · Disposition to issuer (D): 13,766 (derivative) · Disposition to issuer (D): 136,055 (derivative)EDGAR
2023-12-274FLESHNER NEIL E. — Chief Medical Officer, DirectorCode (U): 2,773,045 · Code (U): 233,171 · Code (U): 358 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 60,234 (derivative) · Disposition to issuer (D): 84,257 (derivative)EDGAR
2023-12-274HOGUE GERALD L. — DirectorCode (U): 21,596 · Disposition to issuer (D): 17,936 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative)EDGAR
2023-12-274DEMERS WILLIAM L. — Chief Financial OfficerDisposition to issuer (D): 179,362 (derivative) · Disposition to issuer (D): 16,767 (derivative) · Disposition to issuer (D): 105,360 (derivative) · Disposition to issuer (D): 131,355 (derivative)EDGAR
2023-12-274MARGOLIN YAEL — DirectorDisposition to issuer (D): 1,710 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative)EDGAR
2023-12-274Malik Rajesh — DirectorCode (U): 3,700 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative)EDGAR
2023-12-274Lubner David Charles — DirectorCode (U): 35,400 · Disposition to issuer (D): 3,600 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative)EDGAR
2023-12-274SILBER ALLAN C — Executive Chairman, DirectorCode (U): 4,268,605 · Code (U): 313,884 · Code (U): 38,087 · Code (U): 4,035,655 · Code (U): 71,744 · Disposition to issuer (D): 6,787 (derivative) · +2 moreEDGAR
2023-12-204BVF PARTNERS L P/IL
BIOTECHNOLOGY VALUE FUND L P
BVF I GP LLC
BIOTECHNOLOGY VALUE FUND II LP
BVF II GP LLC
Biotechnology Value Trading Fund OS LP
BVF Partners OS Ltd.
BVF GP HOLDINGS LLC
BVF INC/IL
LAMPERT MARK N
Sale (S): 8,974,245 @ $12.45 · Sale (S): 7,290,667 @ $12.45 · Sale (S): 896,366 @ $12.45EDGAR
2023-11-074MCCANN JOE A. — Chief Executive Officer, DirectorGift (G): 120,000 @ $0EDGAR
2023-11-074SILBER ALLAN C — Executive Chairman, DirectorGift (G): 500,000 @ $0EDGAR
2023-11-024FLESHNER NEIL E. — Chief Medical Officer, DirectorGift (G): 250,000 @ $0EDGAR
2023-06-144Martell Bridget A — DirectorGrant/award (A): 80,503 (derivative) @ $0EDGAR
2023-06-054HOGUE GERALD L. — DirectorGrant/award (A): 44,749 (derivative) @ $0EDGAR
2023-06-054GOODMAN JONATHAN R. — DirectorGrant/award (A): 44,749 (derivative) @ $0EDGAR
2023-06-054MARGOLIN YAEL — DirectorGrant/award (A): 44,749 (derivative) @ $0EDGAR
2023-06-054Malik Rajesh — DirectorGrant/award (A): 44,749 (derivative) @ $0EDGAR
2023-06-054Lubner David Charles — DirectorGrant/award (A): 44,749 (derivative) @ $0EDGAR
2023-03-304MCCANN JOE A. — Chief Executive Officer, DirectorGrant/award (A): 692,643 (derivative) @ $0EDGAR
2023-03-304KELLY JUSTYNA — Chief Operating OfficerGrant/award (A): 98,358 (derivative) @ $0EDGAR
2023-03-304JENSEN JESSICA D. — EVP Clinical DevelopmentGrant/award (A): 136,055 (derivative) @ $0EDGAR
2023-03-304FLESHNER NEIL E. — Chief Medical Officer, DirectorGrant/award (A): 84,257 (derivative) @ $0EDGAR
2023-03-304DEMERS WILLIAM L. — Chief Financial OfficerGrant/award (A): 131,355 (derivative) @ $0EDGAR
2023-03-304SILBER ALLAN C — Executive Chairman, Director, 10% ownerGrant/award (A): 537,322 (derivative) @ $0EDGAR
2023-03-234HOGUE GERALD L. — DirectorOption exercise (M): 17,936 @ $6.97 · Option exercise (M): 17,936 (derivative) @ $0EDGAR
2022-11-304MCCANN JOE A. — Chief Executive Officer, DirectorPurchase (P): 2,160 @ $6.64EDGAR
2022-11-284HOGUE GERALD L. — DirectorPurchase (P): 3,660 @ $6.82EDGAR
2022-11-284Malik Rajesh — DirectorPurchase (P): 3,700 @ $6.66EDGAR
2022-11-284Lubner David Charles — DirectorPurchase (P): 3,600 @ $6.85EDGAR
2022-11-234MARGOLIN YAEL — DirectorPurchase (P): 1,710 @ $6.56EDGAR
2022-11-214GOODMAN JONATHAN R. — DirectorPurchase (P): 6,000 @ $6.33EDGAR
2022-11-214SILBER ALLAN C — Executive Chairman, Director, 10% ownerPurchase (P): 27,603 @ $6 · Purchase (P): 22,397 @ $6.50EDGAR
2022-06-064GOODMAN JONATHAN R. — DirectorGrant/award (A): 25,614 (derivative) @ $0EDGAR
2022-06-064HOGUE GERALD L. — DirectorGrant/award (A): 25,614 (derivative) @ $0EDGAR
2022-06-064MARGOLIN YAEL — DirectorGrant/award (A): 25,614 (derivative) @ $0EDGAR
2022-06-064Malik Rajesh — DirectorGrant/award (A): 25,614 (derivative) @ $0EDGAR
2022-06-064Lubner David Charles — DirectorGrant/award (A): 25,614 (derivative) @ $0EDGAR
2022-05-264FLESHNER NEIL E. — Chief Medical Officer, DirectorSale (S): 564,204 @ $7.51EDGAR
2022-04-054JENSEN JESSICA D. — EVP Clinical DevelopmentGrant/award (A): 13,766 (derivative) @ $0EDGAR
2022-03-314JENSEN JESSICA D. — EVP Clinical DevelopmentGrant/award (A): 213,301 (derivative) @ $0EDGAR
2022-03-314KELLY JUSTYNA — Chief Operating OfficerGrant/award (A): 77,958 (derivative) @ $0EDGAR
2022-03-314DEMERS WILLIAM L. — Chief Financial OfficerGrant/award (A): 105,360 (derivative) @ $0EDGAR
2022-03-314FLESHNER NEIL E. — Chief Medical Officer, DirectorGrant/award (A): 60,234 (derivative) @ $0EDGAR
2022-03-314MCCANN JOE A. — Chief Executive Officer, DirectorGrant/award (A): 381,795 (derivative) @ $0EDGAR
2022-03-314SILBER ALLAN C — Executive Chairman, Director, 10% ownerGrant/award (A): 332,476 (derivative) @ $0EDGAR
2022-02-084/AGOODMAN JONATHAN R. — DirectorGrant/award (A): 35,872EDGAR
2021-12-104KELLY JUSTYNA — Chief Operating OfficerGrant/award (A): 70,000 (derivative) @ $0EDGAR

Recent 8-K events — POINT Biopharma Global Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-12-278-K1.02 — Termination of a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2023-10-038-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-08-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2023-08-038-K4.01 — Changes in Registrant's Certifying Accountant
9.01 — Financial Statements and Exhibits
EDGAR
2023-06-138-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2023-06-058-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2023-02-078-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2022-09-148-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-09-138-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-09-128-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=PNT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs